Tweets
So I think the talk of #ACR21 has been ORAL Surveillance, the phase 3b/4 @US_FDA post-marketing requirement study of tofacitinib vs TNFi in CV risk pts.
I've tried to capture this live through a few threads/tweets, as it happened.
Catch up via this thread of threads @RheumNow
David Liew @drdavidliew ( View Tweet )
4 years 8 months ago
Dr. Aurelie Nahm ( @AurelieRheumo) shares #ACR21 presentation findings on TNF inhibitors and radiographic progression in axSpA
https://t.co/FPs43SGH5R https://t.co/MeM1Js5p4n
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Sinusitis and Pharyngitis with Incident RA: Dr. Richard Conway discusses abstract #0564 presented at the #ACR21 annual meeting.
https://t.co/rWS8VT5obl https://t.co/cHLTf9HPWe
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Drug retention of TNFi vs. secukinumab in AxSpA pts
Abs#911
⭐️46% discontinued either treatment
⭐️TNFi with slightly better drug retention
⭐️Age, BASDAI, BMI did not favor any group
⭐️inefficacy - main reason
#ACR21 @RheumNow https://t.co/ynoomYrTvX
Robert B Chao, MD @doctorRBC ( View Tweet )
4 years 8 months ago
📢No difference in ESRD or mortality with RTX-based vs CYC-based induction regimen in ANCA #Vasculitis
#ACR21 https://t.co/Bdz5t2uyHi
Guy Katz, MD @GuyKatzMD ( View Tweet )
4 years 8 months ago
#ACR21 #ACR2021
Extra pulmonary sarcoidosis ➡️ Cutaneous Sarcoidosis
👌🏻 talk
not posting a tweetorial for the talk as I would suggest go see the talk once
masterclass in Cutaneous sarcoidosis https://t.co/vkWXkq7DXF
EnvisionRheumat @ERheumat ( View Tweet )
4 years 8 months ago
🎉 To celebrate the start of #ACR21, I'm happy to share this slide about #autoantibodies in systemic #autoimmune diseases such as #lupus, sjogren, systemic sclerosis, myosotis...and their main targets 🎯 As you may guess this took me a few hours to assemble... https://t.co/fNmgfOFbiD
Laurent ARNAUD @Lupusreference ( View Tweet )
4 years 8 months ago
Treatment for VEXAS syndrome. It is steroid responsive. Avoid IL-1 inhibitors severe skin reactions at injection site, bone marrow transplant may be curative @RheumNow #ACR21 Session6S410 L Wilson, DO Cordona https://t.co/eQ1KVDiKKV
Dr. Antoni Chan @synovialjoints ( View Tweet )
4 years 8 months ago
Love this COVID ARDS risk calculator put forth by @JYazdanyMD at #ACR21 for our patient's with Rheumatic Diseases. A wonderful resource in talking to our patients about vaccine necessity! @CleClinicMD https://t.co/EA5jVYweHm
Emily Littlejohn @ELittlejohnDO ( View Tweet )
4 years 8 months ago
#ACR21 #ACR2021 Clinical Pearls
🚨 Thread Alert
1/n
💥AAV does not typically cause hard palate lesions➡️consider:
Cocaine induced midline destructive lesion(HNE+)/Malignancy
💥Limited GPA can be ANCA negetive in 50%
💥 oral cavity examination is a must in Rheum https://t.co/RxkLiGdcJt
EnvisionRheumat @ERheumat ( View Tweet )
4 years 8 months ago
#ACR21 #ACR2021
Sjogrens syndrome with pulmonary involvement guidelines
🚨Thread Alert
👉🏻Screen all patients for pulm inv. irrespective of symtopms ➡️ prevlance of lung involvement can be upto 65%
👉🏻Complete PFT includes ➡️ Spirometry➕ DLCO➕ PuseOximetry https://t.co/prFgQESRyF
EnvisionRheumat @ERheumat ( View Tweet )
4 years 8 months ago
